Sichuan Huiyu Pharmaceutical Résultats passés
Passé contrôle des critères 3/6
Sichuan Huiyu Pharmaceutical's earnings have been declining at an average annual rate of -19.8%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 7.4% per year. Sichuan Huiyu Pharmaceutical's return on equity is 7%, and it has net margins of 24.8%.
Informations clés
-19.8%
Taux de croissance des bénéfices
-36.5%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | -7.4% |
| Rendement des fonds propres | 7.0% |
| Marge nette | 24.8% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Recent updates
Sichuan Huiyu Pharmaceutical's (SHSE:688553) Promising Earnings May Rest On Soft Foundations
Nov 02
Sichuan Huiyu Pharmaceutical Co., Ltd. (SHSE:688553) Stock Catapults 38% Though Its Price And Business Still Lag The Market
Oct 29Here's Why Sichuan Huiyu Pharmaceutical (SHSE:688553) Can Manage Its Debt Responsibly
Sep 29Sichuan Huiyu Pharmaceutical (SHSE:688553) Has A Pretty Healthy Balance Sheet
Jun 07Sichuan Huiyu Pharmaceutical Co., Ltd.'s (SHSE:688553) 33% Share Price Surge Not Quite Adding Up
Mar 07Ventilation des recettes et des dépenses
Comment Sichuan Huiyu Pharmaceutical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 1,120 | 278 | 509 | 309 |
| 30 Jun 24 | 1,009 | 136 | 469 | 320 |
| 31 Mar 24 | 932 | 148 | 438 | 322 |
| 31 Dec 23 | 927 | 140 | 440 | 341 |
| 30 Sep 23 | 932 | 103 | 487 | 351 |
| 30 Jun 23 | 1,111 | 148 | 590 | 354 |
| 31 Mar 23 | 1,265 | 168 | 688 | 372 |
| 31 Dec 22 | 1,493 | 249 | 812 | 356 |
| 30 Sep 22 | 1,652 | 294 | 902 | 341 |
| 30 Jun 22 | 1,772 | 358 | 981 | 309 |
| 31 Mar 22 | 1,863 | 430 | 1,020 | 272 |
| 31 Dec 21 | 1,824 | 446 | 972 | 248 |
| 30 Sep 21 | 1,781 | 478 | 1,096 | 213 |
| 30 Jun 21 | 1,664 | 439 | 1,199 | 199 |
| 31 Mar 21 | 1,537 | 405 | 834 | 119 |
| 31 Dec 20 | 1,364 | 343 | 771 | 89 |
| 31 Dec 19 | 707 | 177 | 390 | 56 |
| 31 Dec 18 | 54 | -22 | 57 | 39 |
Des revenus de qualité: 688553 has a large one-off gain of CN¥179.2M impacting its last 12 months of financial results to 30th September, 2024.
Augmentation de la marge bénéficiaire: 688553's current net profit margins (24.8%) are higher than last year (11%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 688553's earnings have declined by 19.8% per year over the past 5 years.
Accélération de la croissance: 688553's earnings growth over the past year (171.2%) exceeds its 5-year average (-19.8% per year).
Bénéfices par rapport au secteur d'activité: 688553 earnings growth over the past year (171.2%) exceeded the Pharmaceuticals industry -1.2%.
Rendement des fonds propres
ROE élevé: 688553's Return on Equity (7%) is considered low.